Is Cue Biopharma, Inc. (CUE) a Buy, Sell, or Hold?
Cue Biopharma, Inc.
NASDAQ:CUE
$31.28 USD
$0.36 (1.16%)
- Volume
- 163.14K
- Average Volume
- 583.16K
- Market Capitalization
- $82.2M
- P/E Ratio
- -5.67
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $45.50
- Year Low
- $4.98
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.57
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Lucinda Warren |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CUE |
| CUSIP | 22978P205 |
| CIK | 0001645460 |
| Web | https://www.cuebiopharma.com |
| Phone | 617 949 2680 |
| Currency | USD |
| Employees | 29 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.16 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.57 |
| Quick Ratio | 3.57 |
| Cash Ratio | 2.22 |
Sales & Book Value
| Annual Sales | $27.47M |
| Price / Sales | 2.51 |
| Cash Flow | -5.12 |
| Price / Cash Flow | -3.34 |
| Price / Book | 6.96 |
Price Target and Rating
| Average Stock Price Forecast | $4.00 |
| High Stock Price Forecast | $7.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | 682.00% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-8.4 |
| Trailing P/E Ratio | -5.67 |
| PEG Ratio | -0.04 |
| P/E Growth | -0.04 |
| Net Income | $-26.6M |
| Net Margin | -59.65% |
| Pretax Margin | -58.12% |
| Return on Equity | -98.30% |
| Return on Assets | -63.23% |
Financials Score
| AltmanZ Score | -11.90 |
| Piotroski Score | 2.00 |
| Working Capital | 19M |
| Total Assets | 30.88M |
| Ebit | -18.85M |
| Market Cap | 81.26M |
| Total Liabilities | 9.27M |
Poll Results
About Cue Biopharma, Inc. (NASDAQ:CUE) Stock
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells t ... o combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
2026-07-13 08:30:00
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases
Cue Biopharma Announces $50.0 Million Private Placement
2026-07-09 21:40:00
BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of $33.21 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 87,500 shares of common stock at a price per pre-funded warrant of $33.209, for gross proceeds of approximately $50.0 million.
2026-06-02 16:05:00
Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a precision immuno-engineering company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced the transition of its board as the Company continues its strategic growth and transformation to support late clinical stage capabilities and activities. Effective May 29, 2026, four independent directors, Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen, have resigned from the board.
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-21 16:05:00
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 3:10 p.m. EDT in New York City.
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
2026-05-14 16:07:00
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 19:07:00
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company's 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Cue Biopharma Announces $30 Million Private Placement
2026-04-30 16:25:00
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, announced today that it has entered into a securities purchase agreement with certain accredited investors for a private placement (the “PIPE financing”) for gross proceeds of approximately $30 million to Cue Biopharma, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about May 4, 2026, subject to the satisfaction of customary closing conditions.
2026-04-30 16:15:00
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases
Frequently Asked Questions
-
What is the current Cue Biopharma, Inc. (CUE) stock price?
-
Cue Biopharma, Inc.(NASDAQ:CUE) stock price is $31.28 in the last trading session. During the trading session, CUE stock reached the peak price of $45.5 while $4.98 was the lowest point it dropped to. The percentage change in CUE stock occurred in the recent session was 1.16% while the dollar amount for the price change in CUE stock was $0.36.
-
CUE's industry and sector of operation?
-
The NASDAQ listed CUE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CUE?
-
Ronald D. Seidel | Co-Founder
Colin G. Sandercock | Senior Vice President of Intellectual Property
Sumita Ray | Chief Legal & Compliance Officer and Corporate Secretary
Steven C. Almo | Co-Founder and Chairman of Scientific & Clinical Advisory Board
Rodolfo J. Chaparro | Co-Founder -
How many employees does CUE have?
-
Number of CUE employees currently stands at 29. CUE operates from 21 Erie Street, Boston, MA 02139, US.
-
Link for CUE official website?
-
Official Website of CUE is: https://www.cuebiopharma.com
-
How do I contact CUE?
-
CUE could be contacted at phone #617 949 2680 and can also be accessed through its website. CUE operates from 21 Erie Street, Boston, MA 02139, US.
-
How many shares of CUE are traded daily?
-
The average number of CUE shares traded daily for last 3 months was 583.16K.
-
What is the market cap of CUE currently?
-
The market value of CUE currently stands at $82.2M with its latest stock price at $31.28